6 Results

People

  1. Drilon
    Drilon
  2. Kris
    Kris
  3. Plodkowski
    Plodkowski
  4. Riely
    Riely
  5. Bergagnini
    Bergagnini
  6. Delasos
    Delasos
  7. Ginsberg
    Ginsberg
  8. Ladanyi
    Ladanyi
  9. Ni
    Ni
  10. Rekhtman
    Rekhtman

Groups

  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (6)
  4. Radiology, Department of (4)
  5. Biostatistics Service (3)
  6. Body Imaging Service (3)
  7. Epidemiology and Biostatistics (3)
  8. Department of Pathology and Laboratory Medicine (2)
  9. GSK Faculty (2)
  10. Human Oncology and Pathogenesis Program (2)
  1. "ret rearrangement"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
  3. Review (1)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (6)
  4. Radiology, Department of (4)
  5. Biostatistics Service (3)
  6. Body Imaging Service (3)

More Groups

People
  1. Alexander Drilon (6)
  2. Andrew Plodkowski (3)
  3. Gregory Riely (3)
  4. Mark Kris (3)
  5. Ai Ni (2)
  6. Isabella Bergagnini (2)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2018 (1)
  4. 2017 (1)
  5. 2016 (1)
  6. 2015 (1)
Publications
  1. Future Oncology (2)
  2. Journal of Thoracic Oncology (2)
  3. Annals of Oncology (1)
  4. Lung Cancer (1)
Publishers
  1. Elsevier Inc. (2)
  2. Future Medicine (2)
  3. Elsevier Ireland Ltd. (1)
  4. Oxford University Press (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
    Review

    Tsuboi, M.; Goldman, J. W.; Wu, Y. L.; Johnson, M. L.; Paz-Ares, L.; Yang, J. C. H.; Besse, B.; Su, W.; Chao, B. H.; Drilon, A.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer
    Journal Article

    Solomon, B. J.; Zhou, C. C.; Drilon, A.; Park, K.; Wolf, J.; Elamin, Y.; Davis, H. M.; Soldatenkova, V.; Sashegyi, A.; Lin, A. B.; more...
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers
    Journal Article

    Drilon, A.; Lin, J. J.; Filleron, T.; Ni, A.; Milia, J.; Bergagnini, I.; Hatzoglou, V.; Velcheti, V.; Offin, M.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
    Journal Article

    Drilon, A.; Bergagnini, I.; Delasos, L.; Sabari, J.; Woo, K. M.; Plodkowski, A.; Wang, L.; Hellmann, M. D.; Joubert, P.; Sima, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Journal Article

    Plodkowski, A. J.; Drilon, A.; Halpenny, D. F.; O'Driscoll, D.; Blair, D.; Litvak, A. M.; Zheng, J.; Moskowitz, C. S.; Ginsberg, M. S.
    Lung Cancer (2015)

    Fulltext@MSK | Save